Related Experiment Videos

Chemotherapy for advanced non-small-cell lung cancer: modest progress, many choices

¹Princess Margaret Hospital, University of Toronto, Toronto, Ontario, Canada. frances.shepherd@uhn.on.ca

Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology

|November 4, 2000

Abstract

No abstract available in PubMed .

Related Concept Videos

Articles linked to this work by shared authors, journal, and citation graph.

Single organ metastatic sites in non-small cell lung cancer: Patient characteristics, treatment patterns and outcomes from a large retrospective Canadian cohort.

Lung cancer (Amsterdam, Netherlands)·2024

Longitudinal health utilities, symptoms and toxicities in patients with ALK-rearranged lung cancer treated with tyrosine kinase inhibitors: a prospective real-world assessment.

Current oncology (Toronto, Ont.)·2020

Osimertinib versus platinum-pemetrexed for patients with EGFR T790M advanced NSCLC and progression on a prior EGFR-tyrosine kinase inhibitor: AURA3 overall survival analysis.

Annals of oncology : official journal of the European Society for Medical Oncology·2020

A randomized trial of the electronic Lung Cancer Symptom Scale for quality-of-life assessment in patients with advanced non-small-cell lung cancer.

Current oncology (Toronto, Ont.)·2020

A phase III, randomized, open-label study of ASP8273 versus erlotinib or gefitinib in patients with advanced stage IIIB/IV non-small-cell lung cancer.

Annals of oncology : official journal of the European Society for Medical Oncology·2019

Real-world benefit of nivolumab in a Canadian non-small-cell lung cancer cohort.

Current oncology (Toronto, Ont.)·2019

See all related articles